{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:49:13Z","timestamp":1793908153386,"version":"4.8.0"},"reference-count":142,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:sec id=\"ab-hrv260003-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Breast cancer is the most common cancer diagnosed in women. Therapies for breast cancer are evolving rapidly, and several are associated with cardiovascular adverse effects, can exacerbate cardiovascular risk factors, or can increase the risk of cardiovascular disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hrv260003-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Advances in screening and treatment have led to earlier diagnosis and improved disease-free survival. For long-term survivors of breast cancer, cardiovascular adverse effects can pose a greater threat to overall long-term health than the cancer itself. Additionally, the increasing incidence of breast cancer in younger, premenopausal women has created a distinct demographic with unique medical needs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hrv260003-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Cardiology practitioners need to remain updated on rapidly evolving breast cancer therapies to care for this growing, unique patient population. The field of cardio-oncology has evolved to address the cardiovascular needs of patients and survivors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamacardio.2026.2546","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:30:34Z","timestamp":1785339034000},"page":"867","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular Health Across the Life Course for Individuals With Breast Cancer"],"prefix":"10.1001","volume":"11","author":[{"given":"Rina","family":"Mauricio","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Cardiology, University of Texas Southwestern, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Deswal","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Ruddy","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Akhter","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming Hui","family":"Chen","sequence":"additional","affiliation":[{"name":"Cardiovascular Health for Cancer Survivors Program, Department of Pediatrics, Division of Genetics and Genomics, Boston Children\u2019s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imo A.","family":"Ebong","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, University of California Davis, Sacramento"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niti R.","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen M.","family":"Harrington","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos H.","family":"Barcenas","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa Pulfer","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Department of Breast Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Heart Vascular Thoracic Institute, Cleveland Clinic, Cleveland Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Nohria","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"hrv260003r1","first-page":"12","article-title":"Cancer statistics, 2024.","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"hrv260003r2","first-page":"409","article-title":"Cancer treatment and survivorship statistics, 2022.","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"hrv260003r4","doi-asserted-by":"publisher","first-page":"e1027","DOI":"10.1016\/S2214-109X(20)30215-1","article-title":"Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study.","volume":"8","author":"Heer","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"8","key":"hrv260003r5","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1161\/CIR.0000000000000556","article-title":"Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association.","volume":"137","author":"Mehta","year":"2018","journal-title":"Circulation"},{"issue":"10","key":"hrv260003r6","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1634\/theoncologist.2017-0672","article-title":"Adjuvant anthracyclines in breast cancer: what is their role?","volume":"23","author":"Shah","year":"2018","journal-title":"Oncologist"},{"issue":"22","key":"hrv260003r7","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"issue":"11","key":"hrv260003r8","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"hrv260003r9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10549-019-05453-z","article-title":"A pooled analysis of the cardiac events in the trastuzumab adjuvant trials.","volume":"179","author":"de Azambuja","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"hrv260003r10","doi-asserted-by":"publisher","DOI":"10.1161\/HCG.0000000000000082","article-title":"Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association.","volume":"14","author":"Okwuosa","year":"2021","journal-title":"Circ Genom Precis Med"},{"issue":"1","key":"hrv260003r11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41574-023-00899-0","article-title":"Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy.","volume":"20","author":"Thomas","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"24","key":"hrv260003r12","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1001\/jama.2019.19191","article-title":"Association of premature natural and surgical menopause with incident cardiovascular disease.","volume":"322","author":"Honigberg","year":"2019","journal-title":"JAMA"},{"issue":"11","key":"hrv260003r13","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1161\/CIR.0000000000000677","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"hrv260003r14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-075859","article-title":"Cardiovascular toxicity of immune therapies for cancer.","volume":"385","author":"Palaskas","year":"2024","journal-title":"BMJ"},{"issue":"8","key":"hrv260003r15","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline.","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"hrv260003r16","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"hrv260003r17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jaccao.2024.12.007","article-title":"Risk stratification for trastuzumab-induced cardiac dysfunction and potential implications for surveillance.","volume":"7","author":"Ali","year":"2025","journal-title":"JACC CardioOncol"},{"issue":"39","key":"hrv260003r18","doi-asserted-by":"publisher","first-page":"25738","DOI":"10.18632\/oncotarget.25008","article-title":"Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives.","volume":"9","author":"Duan","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"hrv260003r19","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/annonc\/mdf035","article-title":"Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil.","volume":"13","author":"Frickhofen","year":"2002","journal-title":"Ann Oncol"},{"key":"hrv260003r20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2017.02.009","article-title":"Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: a retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group.","volume":"76","author":"Kwakman","year":"2017","journal-title":"Eur J Cancer"},{"issue":"14","key":"hrv260003r21","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer.","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"hrv260003r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100772","article-title":"Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.","volume":"8","author":"de Azambuja","year":"2023","journal-title":"ESMO Open"},{"issue":"11","key":"hrv260003r23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s11912-021-01114-x","article-title":"Cardiovascular toxicity of novel HER2-targeted therapies in the treatment of breast cancer.","volume":"23","author":"Dent","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"9793","key":"hrv260003r24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"issue":"18","key":"hrv260003r25","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"9336","key":"hrv260003r26","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","article-title":"First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.","volume":"360","author":"Cuzick","year":"2002","journal-title":"Lancet"},{"issue":"3","key":"hrv260003r27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/annonc\/mdw673","article-title":"Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.","volume":"28","author":"Khosrow-Khavar","year":"2017","journal-title":"Ann Oncol"},{"issue":"11","key":"hrv260003r28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/jcm11113133","article-title":"Aromatase inhibitors and risk of metabolic and cardiovascular adverse effects in breast cancer patients\u2014a systematic review and meta-analysis.","volume":"11","author":"Boszkiewicz","year":"2022","journal-title":"J Clin Med"},{"issue":"3","key":"hrv260003r29","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky035","article-title":"Potential mechanisms of age acceleration caused by estrogen deprivation: do endocrine therapies carry the same risks?","volume":"2","author":"Sehl","year":"2018","journal-title":"J Natl Cancer Inst Cancer Spectr"},{"issue":"5","key":"hrv260003r30","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer.","volume":"372","author":"Francis","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"hrv260003r31","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.mayocp.2016.08.002","article-title":"Accelerated accumulation of multimorbidity after bilateral oophorectomy: a population-based cohort study.","volume":"91","author":"Rocca","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"hrv260003r32","first-page":"3191","article-title":"The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women.","volume":"80","author":"Grey","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"hrv260003r33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S1470-2045(06)70767-7","article-title":"Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.","volume":"7","author":"Buzdar","year":"2006","journal-title":"Lancet Oncol"},{"key":"hrv260003r34","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1038\/sj.bjc.6602692","article-title":"The effects of aromatase inhibitors on lipids and thrombosis.","volume":"93","author":"Bundred","year":"2005","journal-title":"Br J Cancer"},{"issue":"8","key":"hrv260003r35","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/01.cad.0000173478.12981.e1","article-title":"Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy.","volume":"16","author":"Markopoulos","year":"2005","journal-title":"Anticancer Drugs"},{"issue":"8","key":"hrv260003r36","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1093\/annonc\/mdq707","article-title":"The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.","volume":"22","author":"Hozumi","year":"2011","journal-title":"Ann Oncol"},{"issue":"12","key":"hrv260003r37","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2165\/11594170-000000000-00000","article-title":"Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: a systematic review of the literature.","volume":"34","author":"Younus","year":"2011","journal-title":"Drug Saf"},{"issue":"5","key":"hrv260003r38","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/GME.0000000000001729","article-title":"Early and surgical menopause associated with higher Framingham Risk Scores for cardiovascular disease in the Canadian Longitudinal Study on Aging.","volume":"28","author":"Price","year":"2021","journal-title":"Menopause"},{"issue":"4","key":"hrv260003r39","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jtha.2022.12.001","article-title":"Cyclin-dependent kinase 4\/6 inhibitor-associated thromboembolism: a critical evaluation of the current evidence.","volume":"21","author":"Watson","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"12","key":"hrv260003r40","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029361","article-title":"Adverse cardiovascular events associated with cyclin-dependent kinase 4\/6 inhibitors in patients with metastatic breast cancer.","volume":"12","author":"Fradley","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"hrv260003r41","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer.","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"hrv260003r42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.breast.2022.07.011","article-title":"Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer.","volume":"66","author":"Aapro","year":"2022","journal-title":"Breast"},{"issue":"20","key":"hrv260003r43","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer.","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"hrv260003r44","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","article-title":"Anthracycline cardiotoxicity in adult cancer patients: JACC: CardioOncology state-of-the-art review.","volume":"6","author":"Camilli","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"12","key":"hrv260003r45","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1161\/CIRCULATIONAHA.112.001183","article-title":"Ideal cardiovascular health is inversely associated with incident cancer: the Atherosclerosis Risk in Communities study.","volume":"127","author":"Rasmussen-Torvik","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"hrv260003r46","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13058-024-01877-8","article-title":"Association of Life\u2019s Essential 8 cardiovascular health with breast cancer incidence and mortality according to genetic susceptibility of breast cancer: a prospective cohort study.","volume":"26","author":"Zhao","year":"2024","journal-title":"Breast Cancer Res"},{"issue":"2","key":"hrv260003r47","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.amepre.2015.07.039","article-title":"Cardiovascular health and incident cardiovascular disease and cancer: the Women\u2019s Health Initiative.","volume":"50","author":"Foraker","year":"2016","journal-title":"Am J Prev Med"},{"issue":"10","key":"hrv260003r48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1161\/JAHA.116.003954","article-title":"Association between Life\u2019s Simple 7 and noncardiovascular disease: the Multi-Ethnic Study of Atherosclerosis.","volume":"5","author":"Ogunmoroti","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"hrv260003r49","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1161\/ATVBAHA.124.319863","article-title":"Cardiovascular disease and cancer: a dangerous liaison.","volume":"45","author":"Newman","year":"2025","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"hrv260003r50","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/eurjpc\/zwab084","article-title":"Association of premature atherosclerotic cardiovascular disease with higher risk of cancer: a behavioral risk factor surveillance system study.","volume":"29","author":"Jain","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"9","key":"hrv260003r51","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s41591-020-0964-7","article-title":"Myocardial infarction accelerates breast cancer via innate immune reprogramming.","volume":"26","author":"Koelwyn","year":"2020","journal-title":"Nat Med"},{"issue":"7","key":"hrv260003r52","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.117.030816","article-title":"Heart failure stimulates tumor growth by circulating factors.","volume":"138","author":"Meijers","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"hrv260003r53","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaccao.2023.10.002","article-title":"Heart failure post-myocardial infarction promotes mammary tumor growth through the NGF-TRKA pathway.","volume":"6","author":"Tani","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"1","key":"hrv260003r54","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41392-023-01336-4","article-title":"Exosomes secreted from cardiomyocytes suppress the sensitivity of tumor ferroptosis in ischemic heart failure.","volume":"8","author":"Yuan","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"22","key":"hrv260003r55","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.123.066911","article-title":"Small extracellular vesicles from infarcted and failing heart accelerate tumor growth.","volume":"149","author":"Caller","year":"2024","journal-title":"Circulation"},{"issue":"3","key":"hrv260003r56","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.hfc.2022.02.011","article-title":"Myocardial dysfunction in patients with cancer.","volume":"18","author":"Koutroumpakis","year":"2022","journal-title":"Heart Fail Clin"},{"issue":"2","key":"hrv260003r57","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cardfail.2024.08.045","article-title":"Cardio-oncology and heart failure: a scientific statement from the Heart Failure Society of America.","volume":"31","author":"Bloom","year":"2025","journal-title":"J Card Fail"},{"issue":"4","key":"hrv260003r58","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1001\/jamaoncol.2021.6597","article-title":"Aiming at a tailored cure for ERBB2-positive metastatic breast cancer: a review.","volume":"8","author":"Tarantino","year":"2022","journal-title":"JAMA Oncol"},{"issue":"41","key":"hrv260003r59","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"hrv260003r60","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","article-title":"Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.","volume":"188","author":"Dempsey","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"31","key":"hrv260003r61","doi-asserted-by":"publisher","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"issue":"22","key":"hrv260003r62","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1016\/j.jacc.2019.04.006","article-title":"Lessons from primary cardiac prevention trials during trastuzumab therapy: end of one size fits all.","volume":"73","author":"Barac","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"hrv260003r63","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10549-020-06053-y","article-title":"Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function.","volume":"185","author":"Khoury","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"hrv260003r64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2019.06.004","article-title":"Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial.","volume":"1","author":"Leong","year":"2019","journal-title":"JACC CardioOncol"},{"issue":"9","key":"hrv260003r65","doi-asserted-by":"publisher","first-page":"e712","DOI":"10.1093\/oncolo\/oyad086","article-title":"Three-year outcomes following permissive cardiotoxicity in patients on trastuzumab.","volume":"28","author":"Zhou","year":"2023","journal-title":"Oncologist"},{"issue":"5","key":"hrv260003r66","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN Clinical Practice Guidelines in Oncology.","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"hrv260003r67","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10549-023-06997-x","article-title":"Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer.","volume":"201","author":"Rillamas-Sun","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"hrv260003r68","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jaccao.2022.03.005","article-title":"Cardiometabolic comorbidities in cancer survivors: JACC: CardioOncology state-of-the-art review.","volume":"4","author":"Zullig","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"7","key":"hrv260003r69","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1161\/CIRCULATIONAHA.119.044750","article-title":"Aromatase inhibitors and the risk of cardiovascular outcomes in women with breast cancer: a population-based cohort study.","volume":"141","author":"Khosrow-Khavar","year":"2020","journal-title":"Circulation"},{"key":"hrv260003r70","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.breast.2021.07.004","article-title":"Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: a population-based cohort study.","volume":"59","author":"Sund","year":"2021","journal-title":"Breast"},{"issue":"3","key":"hrv260003r71","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10549-022-06714-0","article-title":"Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors.","volume":"196","author":"van Ommen-Nijhof","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"hrv260003r72","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/clc.23114","article-title":"Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? a Medicare population-based study.","volume":"42","author":"Kamaraju","year":"2019","journal-title":"Clin Cardiol"},{"issue":"7","key":"hrv260003r73","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1200\/JCO.22.01065","article-title":"Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT.","volume":"41","author":"Francis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"31","key":"hrv260003r74","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.1200\/JCO.23.00557","article-title":"Adding ovarian suppression to tamoxifen for premenopausal women with hormone receptor-positive breast cancer after chemotherapy: an 8-year follow-up of the ASTRRA trial.","volume":"41","author":"Baek","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"hrv260003r75","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer.","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"hrv260003r76","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1097\/AOG.0b013e3182864350","article-title":"Long-term mortality associated with oophorectomy compared with ovarian conservation in the Nurses\u2019 Health Study.","volume":"121","author":"Parker","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"7","key":"hrv260003r77","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1001\/jamacardio.2016.2415","article-title":"Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis.","volume":"1","author":"Muka","year":"2016","journal-title":"JAMA Cardiol"},{"key":"hrv260003r78","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ahj.2023.10.007","article-title":"Cardiovascular impact of near complete estrogen deprivation in premenopausal women with breast cancer: the CROWN study.","volume":"267","author":"Thomas","year":"2024","journal-title":"Am Heart J"},{"issue":"9","key":"hrv260003r79","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer.","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"hrv260003r80","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer.","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"hrv260003r81","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer.","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"hrv260003r82","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1200\/JCO.2016.69.8480","article-title":"Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures.","volume":"35","author":"van den Bogaard","year":"2017","journal-title":"J Clin Oncol"},{"key":"hrv260003r83","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/1471-2407-10-337","article-title":"Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.","volume":"10","author":"Smith","year":"2010","journal-title":"BMC Cancer"},{"issue":"7","key":"hrv260003r84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133569","article-title":"Efficacy and cardiotoxicity of liposomal doxorubicin-based chemotherapy in advanced breast cancer: a meta-analysis of ten randomized controlled trials.","volume":"10","author":"Xing","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"hrv260003r85","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1200\/JCO.22.02423","article-title":"Dexrazoxane and long-term heart function in survivors of childhood cancer.","volume":"41","author":"Chow","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"hrv260003r86","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaccao.2019.08.003","article-title":"Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer.","volume":"1","author":"Macedo","year":"2019","journal-title":"JACC CardioOncol"},{"issue":"4","key":"hrv260003r87","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1200\/JCO.1997.15.4.1333","article-title":"Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.","volume":"15","author":"Swain","year":"1997","journal-title":"J Clin Oncol"},{"issue":"6","key":"hrv260003r88","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1001\/jama.2023.11887","article-title":"Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial.","volume":"330","author":"Neilan","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"hrv260003r89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/EVIDoa2200097","article-title":"Statins and left ventricular ejection fraction following doxorubicin treatment.","volume":"1","author":"Hundley","year":"2022","journal-title":"NEJM Evid"},{"issue":"6","key":"hrv260003r90","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/ehjcvp\/pvad031","article-title":"Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines.","volume":"9","author":"Thavendiranathan","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"21","key":"hrv260003r91","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1161\/CIRCULATIONAHA.123.064274","article-title":"Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: the Cardiac CARE trial.","volume":"148","author":"Henriksen","year":"2023","journal-title":"Circulation"},{"issue":"16","key":"hrv260003r92","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1161\/CIRCULATIONAHA.125.076616","article-title":"Sacubitril\/valsartan and prevention of cardiac dysfunction during adjuvant breast cancer therapy: the PRADA II randomized clinical trial.","volume":"152","author":"Omland","year":"2025","journal-title":"Circulation"},{"issue":"25","key":"hrv260003r93","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.125.073322","article-title":"Sacubitril-valsartan for the prevention of anthracycline cardiotoxicity in patients with elevated cardiac troponin I concentration during chemotherapy: a double-blind randomized placebo-controlled clinical trial: the SARAH trial.","volume":"152","author":"Bonatto","year":"2025","journal-title":"Circulation"},{"issue":"25","key":"hrv260003r94","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2\u00d72 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.","volume":"143","author":"Heck","year":"2021","journal-title":"Circulation"},{"issue":"10","key":"hrv260003r95","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1001\/jamaoncol.2021.3395","article-title":"Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy: a randomized clinical trial.","volume":"7","author":"Livi","year":"2021","journal-title":"JAMA Oncol"},{"issue":"20","key":"hrv260003r96","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial.","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"hrv260003r97","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jaccao.2024.07.010","article-title":"Preventing cardiac damage in patients treated for breast cancer and lymphoma: the PROACT clinical trial.","volume":"6","author":"Austin","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"8","key":"hrv260003r98","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity.","volume":"35","author":"Pituskin","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"hrv260003r99","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial.","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol"},{"issue":"22","key":"hrv260003r100","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer.","volume":"73","author":"Guglin","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"hrv260003r101","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1177\/1074248418821721","article-title":"Effect of rosuvastatin in preventing chemotherapy-induced cardiotoxicity in women with breast cancer: a randomized, single-blind, placebo-controlled trial.","volume":"24","author":"Nabati","year":"2019","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"18","key":"hrv260003r102","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"5","key":"hrv260003r103","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/S0360-3016(01)02760-2","article-title":"Postmastectomy radiotherapy of the chest wall: dosimetric comparison of common techniques.","volume":"52","author":"Pierce","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"hrv260003r104","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.ijrobp.2012.01.040","article-title":"Prospective assessment of optimal individual position (prone versus supine) for breast radiotherapy: volumetric and dosimetric correlations in 100 patients.","volume":"84","author":"Lymberis","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"hrv260003r105","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13014-019-1329-6","article-title":"Evaluation of a 3D surface imaging system for deep inspiration breath-hold patient positioning and intra-fraction monitoring.","volume":"14","author":"Hamming","year":"2019","journal-title":"Radiat Oncol"},{"issue":"4","key":"hrv260003r106","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0360-3016(00)00512-5","article-title":"Reduction of cardiac volume in left-breast treatment fields by respiratory maneuvers: a CT study.","volume":"47","author":"Lu","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"hrv260003r107","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1161\/01.CIR.96.10.3269","article-title":"Impact of respiratory maneuvers on cardiac volume within left-breast radiation portals.","volume":"96","author":"Chen","year":"1997","journal-title":"Circulation"},{"issue":"2","key":"hrv260003r108","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.prro.2023.11.001","article-title":"Partial breast irradiation for patients with early-stage invasive breast cancer or ductal carcinoma in situ: an ASTRO Clinical Practice Guideline.","volume":"14","author":"Shaitelman","year":"2024","journal-title":"Pract Radiat Oncol"},{"issue":"8","key":"hrv260003r109","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1080\/0284186X.2021.1907860","article-title":"Cardiac substructure exposure in breast radiotherapy: a comparison between intensity modulated proton therapy and volumetric modulated arc therapy.","volume":"60","author":"Loap","year":"2021","journal-title":"Acta Oncol"},{"issue":"1","key":"hrv260003r110","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ijrobp.2015.09.018","article-title":"Initial report of a prospective dosimetric and clinical feasibility trial demonstrates the potential of protons to increase the therapeutic ratio in breast cancer compared with photons.","volume":"95","author":"Bradley","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"hrv260003r111","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025556","article-title":"Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol.","volume":"9","author":"Bekelman","year":"2019","journal-title":"BMJ Open"},{"issue":"22","key":"hrv260003r112","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1200\/JCO.22.00687","article-title":"Exercise, diet, and weight management during cancer treatment: ASCO guideline.","volume":"40","author":"Ligibel","year":"2022","journal-title":"J Clin Oncol"},{"key":"hrv260003r113","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pcad.2024.02.002","article-title":"Exercise-based cardio-oncology rehabilitation for cardiotoxicity prevention during breast cancer chemotherapy: the ONCORE randomized controlled trial.","volume":"85","author":"D\u00edaz-Balboa","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"issue":"4","key":"hrv260003r114","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jaccao.2022.07.006","article-title":"Optimal timing of a physical exercise intervention to improve cardiorespiratory fitness: during or after chemotherapy.","volume":"4","author":"van der Schoot","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"7","key":"hrv260003r115","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1161\/CIRCULATIONAHA.122.062814","article-title":"Exercise for the prevention of anthracycline-induced functional disability and cardiac dysfunction: the BREXIT study.","volume":"147","author":"Foulkes","year":"2023","journal-title":"Circulation"},{"issue":"10","key":"hrv260003r116","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102743","article-title":"New insights into cardioprotection in breast cancer patients undergoing physical exercise during chemotherapy: a systematic review and meta-analysis.","volume":"49","author":"Linhares","year":"2024","journal-title":"Curr Probl Cardiol"},{"issue":"21","key":"hrv260003r117","doi-asserted-by":"publisher","first-page":"e997","DOI":"10.1161\/CIR.0000000000000679","article-title":"Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association.","volume":"139","author":"Gilchrist","year":"2019","journal-title":"Circulation"},{"issue":"20","key":"hrv260003r118","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.2011.39.9014","article-title":"Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum.","volume":"30","author":"Jones","year":"2012","journal-title":"J Clin Oncol"},{"issue":"23","key":"hrv260003r119","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1200\/JCO.2015.65.6603","article-title":"Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer.","volume":"34","author":"Jones","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"hrv260003r120","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jaccao.2022.02.007","article-title":"Physical activity and cardiac function in long-term breast cancer survivors: a cross-sectional study.","volume":"4","author":"Naaktgeboren","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"1","key":"hrv260003r121","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa2502760","article-title":"Structured exercise after adjuvant chemotherapy for colon cancer.","volume":"393","author":"Courneya","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"hrv260003r122","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jaccao.2024.11.003","article-title":"Quality-of-care measures for cardio-oncology: an IC-OS and ACC Cardio-Oncology Leadership Council perspective.","volume":"7","author":"Rao","year":"2025","journal-title":"JACC CardioOncol"},{"issue":"3","key":"hrv260003r123","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/eurheartj\/ehae496","article-title":"Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score.","volume":"46","author":"Rivero-Santana","year":"2025","journal-title":"Eur Heart J"},{"issue":"16","key":"hrv260003r124","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021931","article-title":"Development and validation of a risk score model for predicting the cardiovascular outcomes after breast cancer therapy: the CHEMO-RADIAT score.","volume":"10","author":"Kim","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"hrv260003r125","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.clon.2019.11.008","article-title":"Dynamic Changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy.","volume":"32","author":"Tzolos","year":"2020","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"25","key":"hrv260003r126","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.","volume":"28","author":"Cardinale","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"hrv260003r127","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.","volume":"63","author":"Ky","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"hrv260003r128","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"issue":"4","key":"hrv260003r129","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-guided management of potentially cardiotoxic cancer therapy.","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"41","key":"hrv260003r130","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/eurheartj\/ehae574","article-title":"Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial.","volume":"45","author":"Marwick","year":"2024","journal-title":"Eur Heart J"},{"key":"hrv260003r131","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","article-title":"Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society-one trial.","volume":"94","author":"Cardinale","year":"2018","journal-title":"Eur J Cancer"},{"issue":"12","key":"hrv260003r132","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1001\/jamaoncol.2020.4749","article-title":"Early trastuzumab interruption and recurrence-free survival in ERBB2-positive breast cancer.","volume":"6","author":"Copeland-Halperin","year":"2020","journal-title":"JAMA Oncol"},{"issue":"3","key":"hrv260003r133","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jaccao.2022.07.005","article-title":"Permissive cardiotoxicity: the clinical crucible of cardio-oncology.","volume":"4","author":"Porter","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"3","key":"hrv260003r134","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","article-title":"Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.","volume":"175","author":"Lynce","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"hrv260003r135","first-page":"43","article-title":"American Cancer Society\/American Society of Clinical Oncology breast cancer survivorship care guideline.","volume":"66","author":"Runowicz","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"hrv260003r136","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jaccao.2021.07.008","article-title":"Coronary artery disease in young women after radiation therapy for breast cancer: the WECARE Study.","volume":"3","author":"Carlson","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"7","key":"hrv260003r137","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1001\/jamaoncol.2021.1144","article-title":"Identification of risk of cardiovascular disease by automatic quantification of coronary artery calcifications on radiotherapy planning CT scans in patients with breast cancer.","volume":"7","author":"Gal","year":"2021","journal-title":"JAMA Oncol"},{"issue":"11","key":"hrv260003r138","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.101283","article-title":"Automated breast arterial calcification score is associated with cardiovascular outcomes and mortality.","volume":"3","author":"Allen","year":"2024","journal-title":"JACC Adv"},{"issue":"11","key":"hrv260003r139","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s11886-023-01967-7","article-title":"Tailored to a woman\u2019s heart: gender cardio-oncology across the lifespan.","volume":"25","author":"Chen","year":"2023","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"hrv260003r140","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40959-021-00115-w","article-title":"Rationale and design of the Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial.","volume":"7","author":"Mecinaj","year":"2021","journal-title":"Cardiooncology"},{"issue":"2","key":"hrv260003r141","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jaccao.2024.11.010","article-title":"Withdrawal of cardioprotective therapy in patients with recovered cancer therapy-related cardiac dysfunction.","volume":"7","author":"Shibutani","year":"2025","journal-title":"JACC CardioOncol"},{"issue":"2","key":"hrv260003r142","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-091917","article-title":"HER-SAFE study design: an open-label, randomised controlled trial to investigate the safety of withdrawal of pharmacological treatment for recovered HER2-targeted therapy-related cardiac dysfunction.","volume":"15","author":"Dowsing","year":"2025","journal-title":"BMJ Open"},{"key":"hrv260003r3","unstructured":"National Cancer Institute. Cancer stat facts: female breast cancer, 2025. Accessed February 19, 2025. https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2851850\/jamacardiology_mauricio_2026_rv_260003_1788536051.86537.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:00:55Z","timestamp":1788966055000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2851850"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":142,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2026.2546","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}